Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden

Nordic Journal of Psychiatry

Volumn 68, Issue 6, 2014, Pages 416-427

  Einarson, Thomas R ^a   Vicente, Colin ^b   Zilbershtein, Roman ^b   Piwko, Charles ^b   Bo, Christel N ^c   Pudas, Hanna ^d   Jensen, Rasmus ^e   Hemels, Michiel E H ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b PIVINA Consulting Inc   (Canada)

^c Janssen Cilag   (Norway)

^d Janssen Cilag   (Finland)

^e Janssen Cilag   (Denmark)

Author keywords

Olanzapine pamoate; Paliperidone palmitate; Pharmacoeconomic analysis; Schizophrenia; Sweden

Indexed keywords

CLOZAPINE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; RISPERIDONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HOSPITALIZATION; HUMAN; SCHIZOPHRENIA; SIMULATION; SWEDEN;

OLANZAPINE PAMOATE; PALIPERIDONE PALMITATE; PHARMACOECONOMIC ANALYSIS; SCHIZOPHRENIA; SWEDEN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG COSTS; FEMALE; HALOPERIDOL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PALMITATES; QUALITY-ADJUSTED LIFE YEARS; RISPERIDONE; SCHIZOPHRENIA; SWEDEN;

EID: 84904443823     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2013.852243     Document Type: Article

References (98)

1. Karagianis J, Novick D, Pecenak J, Haro JM, Dossenbach M, Treuer T, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): Baseline characteristics of pan-regional observational data from more than 17, 000 patients. Int J Clin Pract 2009 ; 63 : 1578-88.
2. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia . Schizophr Bull 2004 ; 30 : 279-93. (Pubitemid 38828535)
3. Baxter AJ, Charlson FJ, Somerville AJ, Whiteford HA. Mental disorders as risk factors: Assessing the evidence for the global burden of disease study. BMC Med 2011 ; 9 : 134.
4. F azel S, G rann M, C arlströ m E, L ichtenstein P, L å n gströ m N. Risk factors for violent crime in Schizophrenia: A national cohort study of 13, 806 patients. J Clin Psychiatry 2009 ; 70 : 362-9.
5. Webb RT, L å ngstr ö m N, Runeson B, Lichtenstein P, Fazel S. Violent offending and IQ level as predictors of suicide in schizophrenia: National cohort study. Schizophr Res 2011 ; 130 : 143-7.
6. Fazel S, Buxrud P, Ruchkin V, Grann M. Homicide in discharged patients with schizophrenia and other psychoses: A national case-control study. Schizophr Res 2010 ; 123 : 263-9.
7. Hj ä rthag F, Lars Helldin L, Karilampi U, Norlander T. Illnessrelated components for the family burden of relatives to patients with psychotic illness. Soc Psychiat Epidemiol 2010 ; 45 : 275-83.
8. Foldemo A, Gullberg M, Ek A-C, Bogren L. Quality of life and burden in parents of outpatients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2005 ; 40 : 133-8. (Pubitemid 40259692)
9. Hansson L. Determinants of quality of life in people with severe mental illness. Acta Psychiatr Scand 2006 ; 113 Suppl 429 : 46-50. (Pubitemid 43340888)
10. The NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. National Clinical Guideline 82. London: The British Psychological Society and The Royal College of Psychiatrists ; 2010. Available at: www.nice.org.uk (accessed December 29, 2011).
11. IMS Sweden AB. Available at: http://www.swedenbio.se/en/MembersCompanies/ IMS-Sweden/(accessed January 3, 2012).
12. Kane J, Eerdekens M, Lindenmayer J-P, Keith S, Lesem M, Karcher K. Long-acting injectable risperidone: Effi cacy and safety of the fi rst long-acting atypical antipsychotic. Am J Psychiatry 2003 ; 160 : 1125-32. (Pubitemid 41070972)
13. European Medicines Agency. Assessment report for Zypadhera. Doc. Ref EMEA/608654/2008. Available at: http://www.ema. europa.eu/docs/en-GB/document- library/EPAR-Public-assessment-report/human/000890/WC500054428.pd. Procedure No. EMEA/H/C/000890, 1-63. 2008 (accessed December 29, 2011).
14. European Medicines Agency. Xeplion opinion. Available at: h ttp://www.ema.europa.eu/ema/index.jsp?curl-pages/medicines/human/medicines/ 002105/smops/Positive/human-smop-000162. jsp & murl-menus/medicines/ medicines. jsp & mid-WC0b01ac058001d127 (accessed December 29, 2011).
15. Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007 ; 115 : 260-7. (Pubitemid 46425751)
16. Kasteng F, Eriksson J, Sennf ä lt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand 2011 ; 124 : 214-25.
17. Lindstr ö m E, Eberhard J, Fors BM, Hansen K, Sapin C. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry 2011 ; 65 : 403-13.
18. J ä rbrink K, Kreif N, Benedict A, Locklear J. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2009 ; 25 : 709-6.
19. Hensen M, Heeg B, L ö thgren M, van Hout B. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy 2010 ; 8 : 327-41.
20. Pudas H, Hemels M, Mehnert A, Druais S, Martin M. The costeffectiveness of paliperidone palmitate compared to olanzapine pamoate in the treatment of schizophrenia in Sweden. Value Health 2011 ; 14 : A 560-1.
21. Glazer W, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in " revolving door " schizophrenic patients. J Clin Psychiatry 1996 ; 57 : 337-45. (Pubitemid 26277886)
22. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh J, Davis JM, Lewis DA. Predicting the " revolving door " phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995 ; 152 : 856-61.
23. Einarson TR, Vicente C, Zilbershtein R, Piwko C, B ø CN, Pudas H, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatr 2013 ; 25 : 85-94.
24. Quraishi SN, David A, Brasil MA, Alheira FV. Depot haloperidol decanoate for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 1. Art No: CD001361. DOI: 10.1002/14651858.CD001361.
25. Adams CE, Fenton MP, Quraishi S, David AS. Systematic metareview of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001 ; 179 : 290-9. (Pubitemid 32996037)
26. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010 ; 25 : 685-97.
27. Fleischhacker WW, Gopal S, Lane L, Gassmann-Mayer C, Lim P, Hough D, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011; Jul 22 : 1-12. doi:10.1017/S1461145711001076.
28. Kane J, Detke H, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010 ; 167 : 181-9.
29. Ascher-Svanum H, Peng X, Montgomery W, Faries DE, Lawson AH, Witte MM, et al. Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. Eur Psychiatry 2011 ; 26 : 313-9.
30. Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, et al. Direct transition to long-acting risperidone-Analysis of long-term effi cacy. J Psychopharmacol 2005 ; 19 : 15-21. (Pubitemid 41392293)
31. Lindenmayer J-P, Khan A, Eerdekens M, Van Hove I, Kushner S. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007 ; 17 : 138-44. (Pubitemid 44779189)
32. Lee M, Ko Y, Lee S, Seo Y-J, Kim S-H, Joe S-H, et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006 ; 21 : 399-407. (Pubitemid 44355619)
33. Olivares JM, Rodrigues-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009 ; 24 : 287-96.
34. M ö ller H-J, Llorca P-M, Sacchetti E, Martin SD, Medorie R, Parellada P. Effi cacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005 ; 20 : 121-30.
35. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking fi rst-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007 ; 58 : 482-8. (Pubitemid 46640638)
36. Novick D, Bousono M, Suarez D, Olivares JM, Montejo AL, Haro JM, et al. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29: 972-82. (Pubitemid 41080120)
37. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD006654. DOI:10.1002/14651858.CD006654.pub2.
38. Gopal S, Hough D, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. Effi cacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: A randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010 ; 25 : 247-56.
39. Pandina GJ, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011 ; 35 : 218-26.
40. Hough D, Lindenmayer J-P, Gopal S, Melkote R, Lim P, Herben V, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009 ; 33 : 1022-31.
41. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010 ; 35 : 2072-82.
42. Pandina GJ, Lindenmayer J-P, Lull JM, Lim P, Gopal S, Herben V, et al. A randomized, placebo-controlled study to assess the effi cacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychiatry 2010; 30: 235-44.
43. Lauriello J, Lambert T, Andersen S, Lin D, Taylor C, McDonnell D. An 8-week, double-blind, randomized, placebo controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008 ; 69 : 790-9. (Pubitemid 351838688)
44. European Medicines Agency. Risperdal Consta summary of product characteristics. Available: http://www.ema.europa.eu/docs/en-GB/document- library/Referrals-document/Risperdal-Consta-30/WC500008170.pdf (accessed December 12, 2011).
45. European Medicines Agency. Xeplion summary of product characteristics . Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002105/WC500103317.pdf. 20-4-2010. 8-8-2011 (accessed December 12, 2011).
46. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Schiz Res 2010 ; 116 : 107-17.
47. European Medicines Agency. Zypadhera summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000890/WC500054429.pdf (accessed August 8, 2011).
48. Turner MS, Stewart DW. Review of the evidence for the long-term effi cacy of atypical antipsychotic agents in the treatment of schizophrenia and related psychoses. J Psychopharmacol 2006 ; 20(6 Suppl) : 20-37. (Pubitemid 44583375)
49. Chakos C, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001 ; 158 : 518-26. (Pubitemid 32289814)
50. European Medicines Agency Committe For Proprietary Medicinal Products. Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Leponex and associated names. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Referrals- document/Leponex-30/WC500010966.pdf (accessed December 12, 2011).
51. Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry, Mental Health Policy and Economics; Venice, Italy, 25-27 March 2011.
52. Ascher-Svanum H, Faries D, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006 ; 67 : 453-60.
53. Weiden P, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004 ; 55 : 886-91. (Pubitemid 39025215)
54. Morken G, Widen J, Gr å we R. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia . BMC Psychiatry 2008 ; 8 : 32.
55. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schiz Bull 1995 ; 21 : 419-29.
56. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001 ; 158 : 266-9. (Pubitemid 32116523)
57. Olivares J, Peuskens J, Pecanek J, Resseler S, Jacobs A, Akhras KS. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: Results from a multinational electronic registry. Curr Med Res Opin 2009 ; 25 : 2197-206.
58. Bartk ó G, Herczeg I, Z á dor G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988 ; 77 : 74-6.
59. Heyscue BE, Levin GM, Merrick JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998 ; 49 : 1232-4. (Pubitemid 28414693)
60. Nageotte C, Sullivan G, Duan N, Camp PL. Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol 1997 ; 32 : 49-56. (Pubitemid 27075690)
61. Rittmannsberger H, Pachinger T, Keppelm ü ller P, Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 2004 ; 55 : 174-9. (Pubitemid 38174608)
62. Valenstein M, Copeland La, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001 ; 62 : 545-51. (Pubitemid 32703095)
63. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000 ; 15 : 245-55. (Pubitemid 30660959)
64. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007 ; 23 : 2305-12. (Pubitemid 350033432)
65. Furiak N, Ascher-Svanum H, Klein R, Smolen LJ, Lawson AK, Montgomery W, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: A micro-simulation economic decision model. Curr Med Res Opin 2011 ; 27 : 713-40.
66. Simonsen E, Friis S, Opjordsmoen S, Mortensen EL, Haahr U, Melle I, et al. Early identifi cation of non-remission in fi rst-episode psychosis in a two-year outcome study. Acta Psychiatr Scand 2010; 122: 375-83.
67. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 ; 45 : 789-96.
68. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine ' s effectiveness in schizophrenia: A systematic review and metaanalysis of randomized trials. Am J Psychiatry 1999 ; 156 : 990-9. (Pubitemid 29302789)
69. Arvidsson H, Ericson BG. The development of psychiatric care after the mental health care reform in Sweden. A case register study. Nord J Psychiatry 2005 ; 59 : 186-92. (Pubitemid 40946277)
70. Cullberg J, Mattsson M, Levander S, Holmqvist R, Tomsmark L, Elingfors C, et al. Treatment costs and clinical outcome for fi rst episode schizophrenia patients: A 3-year follow-up of the Swedish Parachute Project and Two Comparison Groups. Acta Psychiatr Scand 2006 ; 114 : 274-81. (Pubitemid 44389278)
71. Damen J, Thuresson P-O, Heeg B, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy 2008 ; 6 : 189-97.
72. Lindstr ö m E, Eberhard J, Levander S. Five-year follow-up during antipsychotic treatment: Effi cacy, safety, functional and social outcome. Acta Psychiatr Scand 2007 ; 116 Suppl 435 : 5-16. (Pubitemid 47621730)
73. Malm U, Ivarsson B, Allebeck P, Falloon IRH. Integrated care in schizophrenia: A 2-year randomized controlled study of two communitybased treatment programs. Acta Psychiatr Scand 2003; 107: 415-23. (Pubitemid 36683416)
74. Regionala priser och ers ä ttningar f ö r s ö dra sjukv å rdsregionen 2011. Available at: http://www.skane.se/upload/Webbplatser/ Sodra%20 regionvardsnamnden/prislista/2011/helaprislistan2011.pdf (accessed January 1, 2012).
75. Lindstr ö m E, Eberhard J, Neovius M, Levander S. Costs of schizophrenia during 5 years. Acta Psychiatr Scand 2007; 116 Suppl 435: 33-40. (Pubitemid 47621733)
76. Regionala priser och ers ä ttningar f ö r s ö dra sjukv å rdsregionen, 2009. Available at: http://www.skane.se/upload/Webbplatser/ Sodra%20 regionvardsnamnden/prislista/2009/helaprislistan2009.pdf (accessed January 1, 2012).
77. Regionala priser och ers ä ttningar f ö r s ö dra sjukv å rdsregionen 2008. Available at: http://www.skane.se/upload/Webbplatser/ Sodra%20 regionvardsnamnden/prislista/2008/helaprislistan2008.pdf (accessed January 1, 2012).
78. Landstinget dalrna prislista, 2011. Available at: http://www.externt9. lul.se/svn/dalarna11.xls (accessed January 1, 2012).
79. TLV (Dental and Pharmaceutical Benefi ts Agency). Available at: www.tlv.se (accessed January 1, 2012).
80. Statistics Sweden. Consumer price index. Available at: h ttp://www. scb.se/Pages/Product-33783.aspx (accessed January 1, 2012).
81. Dossenbach M, Erol A, el Mafoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, et al. Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone and haloperidol. J Clin Psychiatry 2 004; 6 5: 3 12-2 1.
82. Detke H, McDonnell D, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: Analysis of cases. BMC Psychiatry 2010 ; 10 : 32.
83. Alphs L, Gopal S, Karcher K, Kent J, Sliwa JK, Kushner S, et al. Are long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium sedation syndrome? An assessment of safety databases. Curr Drug Saf 2011; 6: 43-5.
84. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 ; 353 : 1209-23. (Pubitemid 41345943)
85. All Wales Medicines Strategy Group. F inal appraisal report: Olanzapine depot (ZypAdhera), Lilly UK. Advice No: 1510, October 2010. Available at: http://www.wales.nhs.uk/sites3/Documents/371/olanzapine%20depot%20(ZypAdhera) %20schizophrenia.pdf (accessed January 1, 2012).
86. Farahati F, Boucher M, Williams R, Williams R, Herrmann N, Silverman M, et al. Atypical antipsychotic monotherapy for schizophrenia: Clinical review and economic evaluation of fi rst year of treatment [Technology report number 91]. Ottawa: Canadian Agency for Drugs and Technologies in Heath ; 2007.
87. Dental and Pharmaceutical Benefi ts Agency. G eneral guidelines for economic evaluations from the Pharmaceutical Benefi ts Board (LFNAR 2003:2). Available at: http://www.ispor.org/PEguidelines/source/Guidelines-in-Sweden.pdf (accessed December 12, 2011).
88. Briggs A, Wild D, Lees M, Reaney M, Dursun S, David Parry D, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation. Health Qual Life Outcomes 2008 ; 6(Nov 28) : 105.
89. Cummins C, Stevens A, Kisely S. The use of olanzapine as a fi rst and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee Report. Birmingham: Department of Public Health & Epidemiology, University of Birmingham; 1998.
90. Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schiz Res 2004; 71: 155-75.
91. Oh PI, Lanct ô t KL, Mittmann N, Iskedjian M, Einarson TR. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001 ; 4 : 137-56. (Pubitemid 34094047)
92. Revicki DA, Shakespeare A, Kind P. Preferences for schizophreniarelated health states: A comparison of patients, caregivers and psychiatrists . Int Clin Psychopharmacol 1996 ; 11 : 101-8.
93. Liu-Seifert H, Osuntokun OO, Feldman PD. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Compr Psychiatry 2012 ; 53 : 107-15.
94. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: A systematic review and metaanalysis of second-generation antipsychotics versus fi rst-generation antipsychotics. Mol Psychiatry 2011 Nov; doi:10.1038/mp.2011.143.
95. Devadason P. Practical limitations of prescribing olanzapine depot (Relprevv). Australas Psychiatry 2010 ;l 18 : 269.
96. Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ 2012 ; 15 : 844-61.
97. ATC/DDD Index 2011. Available at: http://www.whocc.no/atc-ddd-index/ (accessed January 12, 2011).
98. Einarson TR, Hemels MEH. Validation of an economic model of paliperidone palmitate for chronic schizophrenia. J Med Econ 2013 ; 16 : 1267-74.